

1 **PREDICTIVE IMMUNOLOGICAL, VIROLOGICAL, AND ROUTINE**
2 **LABORATORY MARKERS FOR CRITICAL COVID-19 ON**
3 **ADMISSION.**

4 **Immunocovid study**

5 **Authors:** Mercedes García-Gasalla¹, Juana M Ferrer², Pablo A Fraile-Ribot³, Adrián Ferre-
6 Beltrán¹, Adrián Rodríguez⁴, Natalia Martínez-Pomar², Luisa Ramon-Clar⁵, Amanda
7 Iglesias⁶, Inés Losada-López⁴, Francisco Fanjul¹, Joan Albert Pou¹, Isabel Llompart-
8 Alabern⁷, Nuria Toledo⁵, Jaime Pons², Antonio Oliver³, Melchor Riera¹, Javier Murillas¹.

9 ¹Internal Medicine, Hospital Universitari Son Espases-Institut d'Investigació Sanitària Illes
10 Balears (IdISBa), Palma, Balearic Islands, Spain.

11 ²Immunology, Hospital Universitari Son Espases-Institut d'Investigació Sanitària Illes
12 Balears (IdISBa), Palma, Balearic Islands, Spain.

13 ³Microbiology, Hospital Universitari Son Espases-Institut d'Investigació Sanitària Illes
14 Balears (IdISBa), Palma, Balearic Islands, Spain.

15 ⁴Internal Medicine, Hospital Universitari Son Llàtzer-Institut d'Investigació Sanitària Illes
16 Balears (IdISBa), Palma, Balearic Islands, Spain.

17 ⁵Pneumology, Hospital Universitari Son Espases-Institut d'Investigació Sanitària Illes
18 Balears (IdISBa), Palma, Balearic Islands, Spain.

19 ⁶CIBER de Enfermedades Respiratorias, Hospital Universitari Son Espases-Institut
20 d'Investigació Sanitària Illes Balears (IdISBa), Palma, Balearic Islands, Spain, CIBERES,
21 Spain

22 ⁷Análisis Clínicos. Hospital Universitari Son Espases, Palma, Balearic Islands, Spain

23

24 **Corresponding Author:**

25 Mercedes García-Gasalla . Internal Medicine, Hospital Universitari Son Espases-Institut
26 d'Investigació Sanitària Illes Balears (IdISBa), Crtra Valldemossa , 79. 07120. Palma,
27 Balearic Islands, Spain.

28 email: mercedesggasalla@yahoo.es and mgarcia5@ssib.es

29 tel 00-34- 871205371

30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31

32

33 **ABSTRACT**

34 **Introduction:** Early identification of COVID-19 patients at risk of critical illness is challenging
35 for clinicians. Immunological, virological, and routine laboratory markers to be used in
36 addition to clinical data are needed.

37 **Aim and methods:** Blood tests to measure neutrophil/lymphocyte ratio (NLR), levels of
38 ferritin, CRP, D-dimer, complement components (C3, C4), lymphocyte subsets, and
39 cytokines, and SARS-Cov2 RT-PCR tests were performed in COVID-19 confirmed cases
40 within 48 hours of admission. Cycle threshold (Ct) values were determined by RT-PCR from
41 oral or nasopharyngeal swabs on the day of admission. Severity of symptoms was
42 categorized as mild (grade 1), severe (grade 2), and critical (grade 3).

43 **Results:** 120 patients were included. COVID-19 was mild in 49, severe in 32, and
44 critical in 39. Ferritin >370 ng/mL (OR 16.4, 95% CI 5.3-50.8), D-dimer >440 ng/mL (OR 5.45,
45 95% CI 2.36-12.61), CRP >7.65 mg/dL (OR 11.54, 95% CI 4.3-30.8), NLR >3.77 (OR 13.4,
46 95% CI 4.3-41.1), IL-6 >142.5 pg/mL (OR 8.76, 95% CI 3.56-21.54), IL-10 >10.8 pg/mL (OR
47 16.45, 95% CI 5.32-50.81), sIL-2 α (sCD25) >804.5 pg/mL (OR 14.06, 95% CI 4.56-43.28),
48 IL-1Ra >88.4 pg/mL (OR 4.54, 95% CI 2.03-10.17), and IL-18 >144 pg/mL (OR 17.85, 95%
49 CI 6.54-48.78) were associated with critical COVID-19 in the univariate age-adjusted
50 analysis. In the multivariate age-adjusted analysis, this association was confirmed only for
51 ferritin, CRP, NLR, IL-10, sIL-2 α , and IL-18. T, B, and NK cells were significantly decreased
52 in critical patients. SARS-CoV-2 was undetected in blood except in 3 patients with
53 indeterminate results. Ct values determined by RT-PCR from oral/nasopharyngeal swabs on
54 admission were not related to symptom severity.

55 **Conclusion:** levels of ferritin, D-dimer, CRP, NLR, and cytokines and cytokine receptors IL-
56 6, IL1-Ra, sCD25, IL-18, and IL-10, taken together with clinical data, can contribute to the
57 early identification of critical COVID-19 patients.

58

59 **Keywords:** critical Covid-19; IL-6; sCD25, IL-18; IL-10; SARS-Cov 2 RT-PCR Ct values.

60

61 **Background**

62 The first cases of coronavirus disease 2019 (COVID-19) caused by the novel
63 coronavirus 2 (SARS-CoV-2) were reported in China in December 2019 and rapidly escalated
64 to a global pandemic with millions of confirmed cases worldwide, with numbers still rising [1-
65 3]. Most COVID-19 cases are asymptomatic or result in only mild disease. However, in a
66 substantial percentage of patients, respiratory illness requiring hospital care develops.
67 Pulmonary disease can progress to critical illness with extensive lung damage and
68 hypoxemic respiratory failure requiring prolonged ventilatory support [1]. Strategies for
69 predicting the risk of disease progression are needed. Different clinical and laboratory
70 markers to be used in the emergency setting are under investigation [4, 5], and several score
71 models have been developed [6]. Identifying patients at high risk of critical illness on
72 admission is challenging for clinicians, but is crucial for screening patients in need of more
73 intensive treatment to improve prognosis. Several COVID-19 studies have shown an
74 association between increased levels of serum inflammatory markers and proinflammatory
75 cytokines and severe disease [7, 8]. A number of cytokines and chemokines have been
76 implicated in the induction of the so-called cytokine storm [9-11] and some, notably interleukin
77 (IL) 6, are now considered as both prognostic factors and therapeutic targets [12, 13]. Some
78 investigators have also suggested a prognostic value of semi-quantitative real-time reverse

79 transcription polymerase chain reaction (RT-PCR) from nasopharyngeal swabs, which
80 determines viral load through cycle threshold (Ct) values, with lower Ct values associated
81 with worse outcomes [14]. Moreover, SARS-CoV-2 viremia has been reported in severe
82 cases [15].

83 The purpose of our study was to identify routine laboratory, immunological and
84 virological biomarkers to be used together with clinical data for early identification of patients
85 at risk of developing critical illness.

86 **Methods**

87 Participants and study design

88 Patients admitted to Son Espases and Son Llàtzer hospitals in Palma de Mallorca
89 between 17 April and 20 July 2020 with positive nasopharyngeal swab RT-PCR test who
90 accepted to participate in the study were included. Blood samples to measure the
91 neutrophil/lymphocyte ratio (NLR), ferritin, C-reactive protein (CRP), D-dimer, complement
92 components (C3, C4), lymphocyte subsets, and serum levels of cytokines, and to perform
93 SARS-CoV-2-RT-PCR testing were obtained within the first 48 hours of admission.

94 The severity of signs and symptoms developed during hospitalization was categorized as
95 mild (grade 1), severe (grade 2), and critical (grade 3). Mild disease was established when
96 the patient had symptoms without pneumonia or had mild pneumonia; severe disease was
97 established when dyspnea was associated with a respiratory rate ≥ 30 /min or blood oxygen
98 saturation $< 93\%$, or a partial pressure of arterial oxygen to fraction of inspired oxygen ratio
99 < 300 , and/or lung infiltrates $> 50\%$ within 24 to 48 hours from admission; critical disease
100 was established for cases with respiratory failure, septic shock, and/or multiple organ
101 dysfunction or failure [1]. The most severe category developed during hospitalization was
102 selected, and it occurred in the first 72h of admission in all cases.

103

104 Procedures

105 Routine blood examinations included leukocyte, neutrophil, and lymphocyte counts
106 (cells*10³/μL) and percentages. Serum biochemical tests recorded were ferritin (ng/L)
107 determined by chemiluminescence immunoassay in architect i2000 equipment , CRP
108 (mg/dL), and D-dimer (μg/L) quantified by immunoturbidimetry in architect 16.000,
109 Immunological tests recorded were serum complement levels (C3, C4), lymphocyte subset
110 cell counts (cells*10³/μL) and percentages using flow cytometry, and plasma cytokine
111 levels. We used an enzyme-linked immunosorbent assay (ELISA, DIAsource
112 ImmunoAssays,SA, Belgium) to measure serum levels of IL-6, a chemiluminescence assay
113 (IMMULITE, Siemens, Germany) to determinate serum soluble IL-2 receptor alpha (sIL-2rα
114 or sCD25), and a human cytokine magnetic bead panel (Merck Millipore, Billerica, MA, USA)
115 to measure levels of other cytokines associated with cytokine storm: IL-1β, IL-1 receptor
116 antagonist (IL-1Ra), IL-6, IL-8, IL-17A, IL-18, IL-22, interferon (IFN), tumor necrosis factor
117 alpha (TNF-α), and IL-10.

118 SARS-CoV-2 was determined in nasopharyngeal swab specimens (within 16 hours of their
119 collection) and in plasma samples stored at -70°C until testing. Nucleic acids were extracted
120 using a Hamilton automated extraction platform and the amplification process was performed
121 in a Bio-Rad CFX96 real-time PCR detection instrument (Bio-Rad, Hercules, CA) using two
122 commercial RT-PCR kits: Allplex 2019-nCoV (Seegene, Seoul, Korea), which detects the
123 presence of 3 target genes E gene, RdRP gene, and N gene; and LightMix® Modular SARS-
124 CoV (COVID-19) E-gene (TIB MOLBIOL, Berlin, Germany).

125 In order to assess the correlation between semi-quantitative viral load values and pattern of
126 disease severity, Ct values were recorded for each gene.

127

128 Statistical analysis

129 Categorical variables were expressed as numbers and percentages, and continuous
130 variables as mean and standard deviation (SD), or median and interquartile range (IQR)
131 values. Proportions for categorical variables were compared using the χ^2 test. The
132 independent group t test and the Mann-Whitney U test were used for the comparison of
133 continuous normally and not normally distributed variables, respectively. Normal distribution
134 was studied by plotting histograms and with the Shapiro-Wilk test. A Kruskal Wallis test was
135 performed to compare the difference between the three groups of patients classified
136 according to disease severity. The receiver operating characteristic (ROC) curve was used
137 to assess the diagnostic value of the biological markers, and the optimal cut-off value
138 providing the best trade-off between sensitivity and specificity was selected with the Youden
139 index. Univariate and multivariate age-adjusted logistic regression analyses were performed
140 to explore the association between laboratory parameters and the risk of developing critical
141 disease, using the values provided by the Youden index as cut-off points.

142 All statistical analyses were performed using SPSS (Statistical Package for the Social
143 Sciences) version 22.0 software (SPSS Inc.). Two-sided *P* values of less than .05 were
144 considered statistically significant.

145

146 **Results**

147 Between 17 April and 20 July 2020, 120 laboratory-confirmed SARS-CoV-2 patients
148 accepted to participate and were included in the study. There were 55 women and 65 men,
149 and median age was 59 years (29-89). COVID-19 was considered mild in 49 patients, severe

150 in 32 and critical in 39 cases. Twenty patients (16.67%) died during hospitalization. The death
151 of 2 of them was not related to COVID-19 but to an associated malignancy. Pulmonary
152 embolism (PE) was diagnosed in 15 patients (12.5%), and of these, 9 had critical COVID-19.
153 Demographic characteristics and comorbidities of SARs-COV-2 infected patients with mild,
154 severe, and critical disease are presented in Table 1. Compared with patients with mild or
155 severe disease, critically ill patients were significantly more likely to be men ($p = .00$), have
156 older age ($p = .036$), concomitant hypertension ($p = .036$), and diabetes mellitus ($p = .023$).

157 -Laboratory data:

158 Laboratory markers were tested on admission (Table 2), and their cut-off values were
159 calculated to predict the risk of developing critical COVID-19 (Fig 1). In the univariate
160 analysis, ferritin > 370 ng/mL (OR [odds ratio] 16.4, 95% confidence interval [CI] 5.3-50.8),
161 D-dimer >440 ng/mL (OR 5.45, 95% CI 2.36-12.61), CRP > 7.65 mg/dL (OR 11.54, 95% CI
162 4.3-30.8), and NLR > 3.77 (OR 13.4, 95% CI 4.3-41.1) predicted the development of critical
163 COVID-19. In the multivariate analysis, the risk was statistically significant for ferritin (OR 8.1,
164 95% CI 2.1-30.6), NLR (OR 6.2, 95% CI 1.6-24.0), and CRP (OR 4.9, 95% CI 1.4-17.4), but
165 not for D-dimer.

166 -Immunological results:

167 Serum complement levels were measured on admission. Median values of C3 and C4
168 levels in critical COVID-19 patients (group 3) were 116 mg/dL (108.0–127.7) and 26.0 mg/dL
169 (17.0-39.0), respectively, whereas in mild and severe patients (groups 1 and 2) the median
170 values were 125 mg/dL (105.5–145.5) and 26.5 mg/dL (21.0-33.0), respectively ($P > .05$).
171 Low C4 levels (<20 mg/dL) were found in 5/15 (33.3%) patients with PE versus 22/105
172 (20.9%) patients without PE ($p > .05$) and in 10/39 (25.6%) patients with critical disease
173 versus 9/49 (18.4%) patients with mild disease ($p > .05$)

174 Levels of IL-6, sIL-2 α (sCD25), IL-1 β , IL-1Ra, IL-8, IL-17A, IL-18, IL-22, IFN, IL-10,
175 and TNF- α were analyzed (Table 3). IL-6, IL-10, sIL-2 α , IL-1Ra, and IL-18 levels were
176 significantly elevated on admission in patients who developed a critical disease. A cut-off
177 value for each of these markers was determined to predict the risk of developing a critical
178 COVID-19 (Figure 1). Values of IL-6 > 142.5 pg/mL, IL-10 > 10.8 pg/mL, IL1 β > 4.68pg/ml ,
179 sIL-2 α > 804.5 pg/mL, IL-1Ra > 88.4 pg/mL, and IL-18 > 144 pg/mL were associated with
180 the development of critical COVID-19 in the age-adjusted univariate analysis. In the age-
181 adjusted multivariate analysis, this association was confirmed only for IL-10, sIL-2 α , and IL-
182 18 (Table 4).

183 Lymphocyte subsets were analyzed in peripheral blood in a subgroup of patients on
184 admission. The total number of T, B, and natural killer (NK) cells was significantly decreased
185 in patients with more severe disease (Table 5). Neither a univariate nor a multivariate analysis
186 was performed due to the small number of patients with critical COVID-19.

187 -Microbiological study:

188 Oropharyngeal or nasopharyngeal swab samples obtained from 89 patients on the day
189 of admission were tested for SARS-CoV-2 by RT-PCR either targeting E, N, and RdRP genes
190 (72 patients) or E gene alone (17 patients). No significant differences in median Ct values
191 according to symptom severity were observed (Table 6). No statistically significant
192 differences between Ct values and number of days from symptom onset on admission or
193 mortality were found either. Ct values >34 (associated with a low viral load) for the E gene
194 on hospital admission were found in 16/89 (17.9%) patients; 2 had critical COVID-19 and 5
195 had severe COVID-19. Additionally, the N and RdPR genes were studied in 8/16 patients
196 and a Ct value >34 was found in 3 cases. SARS-CoV-2 RT-PCR was performed in blood

197 samples from 73 patients. All the results were interpreted as negative except in 3 cases that
198 gave an indeterminate result (only a Ct >38 for the N gene was detected).

199 **Discussion**

200 Our study has identified a number of biomarkers which, in combination with the clinical
201 classification, may be used to better evaluate the severity of COVID-19 and optimize
202 therapeutic management strategies. Moreover, we propose cut-off values for each of these
203 markers to predict the risk of developing critical COVID-19. sCD25, IL-1Ra, and IL-18 are of
204 special interest as they have rarely been described as prognostic factors in COVID-19.

205 CRP, D-dimer, and ferritin have been described early in the pandemic as markers of
206 hyperinflammatory state and disease severity [7, 16, 17], and COVID-19 guidelines have
207 suggested that measuring their levels may have prognostic value [18]. Ferritin may be
208 produced by activated pulmonary macrophages, and COVID-19 systemic inflammation is
209 now considered as part of the spectrum of hyperferritinemic syndromes because a significant
210 increase in ferritin levels has been found in severe compared with non-severe COVID-19
211 patients [19-22]. Similarly, CRP and D-dimer have been identified as prognostic markers, and
212 cut-off values have been suggested in several studies: CRP > 4.96 mg/dL and D-dimer >
213 2600 ng/mL have been associated with critical illness in a study in China [7], whereas D-
214 dimer > 500 ng/mL or >1000 ng/mL was found to be a significant risk factor for death in other
215 studies [17, 23, 24]. However, in our study, the cut-off value of 440 ng/mL proposed for D-
216 dimer was associated with a higher risk of developing critical disease in the univariate
217 analysis but not in the multivariate analysis and neither was it associated with PE since D-
218 dimer concentrations >440 ng/mL were observed on admission in only 9/15 patients who
219 were later diagnosed with PE during hospitalization. NLR has already proven its prognostic
220 value in cardiovascular and inflammatory diseases, in several types of cancer, and in some

221 bacterial diseases [25]. Since the beginning of the COVID-19 pandemic, lymphopenia and
222 increased NLR have been widely described as markers of severity [9, 16, 17]. Different
223 mechanisms have been proposed for COVID-19-related lymphopenia: T cell exhaustion,
224 apoptosis, pyroptosis, and a direct cytopathic effect of the virus [26]. Flow cytometric
225 evaluation was useful in our study to investigate this lymphopenia. We found a significant
226 reduction of all lymphocyte subsets —CD3+, CD4+, and CD8+ T cells (with no inversion in
227 the CD4+/CD8+ ratio), NK cells, and B lymphocytes— in severe/critical patients compared
228 to mild patients, in line with findings from other studies [16, 27, 28]. In addition, CD3+CD8+ T
229 cell counts ≤ 75 cells/ μ L have been associated with death [23].

230 Immunological markers were investigated. Since hypocomplementemia has been
231 reported in several viral infections and activation of the complement system and vascular
232 deposition of complement components have been found in SARS-CoV thrombotic
233 microangiopathy, the complement system was assessed. Neither our study nor a previous
234 report found lower C3 or C4 levels in severe COVID-19 patients [29], but a relationship
235 between PE and low C4 levels cannot be excluded. However, a recent study addressed the
236 activation of the complement system measuring C3a, C3c, and the terminal complement
237 complex and found significant higher levels in ICU COVID-19 patients compared to non-ICU
238 COVID-19 patients [30].

239 Eleven cytokines or their receptors were tested on admission in the 120 patients, and
240 IL-6, IL-10, IL1 β , IL-1Ra, sIL-2 α (sCD25), and IL-18 were found to be of prognostic value.

241 High serum levels of IL-6 have been widely described as a hallmark of severity in
242 COVID-19 [9, 11, 16, 31, 32]. IL-6 plays a central role in the cytokine storm as it induces
243 cytotoxic T lymphocytes, promotes Th17 cell lineage, inhibits regulatory T cells, and activates
244 B cells and antibody production. A recent systematic review and meta-analysis [33]

245 concluded that threefold higher serum IL-6 levels were found in patients with severe COVID-
246 19 compared with those with noncomplicated disease, and that such increased levels were
247 significantly associated with adverse clinical outcomes, including ICU admission, acute
248 respiratory distress syndrome, and death. Furthermore, several studies have suggested a
249 benefit of IL-6 and IL-6 receptor antagonists for the management of critical COVID-19
250 patients [12, 21, 34].

251 We found that both IL-1Ra and IL-10 anti-inflammatory cytokines were significantly
252 elevated in critical cases compared with moderate or severe ones. IL-10 has been described
253 early in the pandemic as a marker of severe disease [9, 31]. IL-1Ra produced by activated
254 macrophages is a competitive antagonist for IL-1 and controls inflammatory responses,
255 modulating the production of other inflammatory cytokines. IL-1Ra has been previously
256 investigated in several small studies and increased levels have been found in severe clinical
257 cases [35, 36], supporting its role as an important marker of disease severity.

258 IL-18 is a proinflammatory cytokine that facilitates IFN- γ production by Th1 cells in
259 conjunction with IL-12 and activation of CD8+ T cells. In our study, significantly higher IL-18
260 levels were found in critical patients compared with moderate or mildly ill patients. A
261 correlation between IL-18 and the severity of COVID-19 had only been found in a small study
262 [8], but a recent study has suggested this cytokine has a prognostic value [37].

263 The serum sIL-2 α (sCD25) level is considered an important disease marker in
264 hemophagocytic syndromes/hemophagocytic lymphohistiocytosis [38]. However, its value as
265 a prognostic factor in COVID-19 has been rarely reported. A small preliminary study in China
266 with 21 patients found significant increased serum sCD25 levels in critical patients compared
267 with patients with moderate disease [16], and the authors have suggested that sCD25 may
268 act as a negative regulatory factor for T cells, contributing to lymphopenia. Other investigators

269 have suggested the relevance of the sIL-2 α /lymphocyte index for early identification of
270 severe COVID-19 and prediction of the clinical progression of the disease [39]. In our study,
271 sCD25 was accurate in estimating the risk of complicated disease, as a cut-off value of >
272 804.5 pg/mL yielded a 73.3% sensitivity and 76.0% specificity for developing critical COVID-
273 19.

274 Finally, virological markers were studied as prognostic factors for the development of
275 severe disease, but our results failed to confirm any association. We did not find a correlation
276 between Ct values determined by RT-PCR from nasopharyngeal swabs specimens and
277 severity of the disease. Previous studies have reported conflicting results: a correlation
278 between lower Ct values (representing higher viral loads) in respiratory samples and greater
279 disease severity has been shown in certain studies [40-43], but other studies of non-SARS-
280 CoV-2 respiratory viruses have not shown such correlation [14, 40-42, 44]. SARS-CoV-2
281 testing of blood samples from critical COVID-19 patients who died was negative in 70 patients
282 and indeterminate in 3. The detection of SARS-CoV in plasma was associated with critical
283 disease in the 2003 SARS pandemic [45], but COVID-19 studies have been scarce. One
284 study detected SARS-CoV-2 viremia in up to 41% of patients admitted in a hospital in
285 Zhejiang province, China [46].

286 Our study has some important limitations: it took place in a very specific geographic
287 area (two hospitals in the Mediterranean island of Majorca), and the number of patients is
288 small. In addition, patients were admitted at different times during the course of the COVID-
289 19 pandemic and received different therapies, which may have altered the outcomes.

290

291 In conclusion, ferritin, D-dimer, CRP, NLR, and cytokines and cytokine receptors IL-6,
292 IL-1Ra, sIL-2 α (sCD25), IL-18, and IL-10 contribute, in association with clinical data, to the
293 early identification of patients at risk of critical COVID-19 and susceptible of a more intensive

294 therapy. Further studies evaluating these biomarkers and their ability for predicting critical
295 COVID-19 are needed.

296

297 List of abbreviations

298 Ct values: Cycle threshold values; CRP: C-reactive protein; IL-1Ra : IL-1 receptor
299 antagonist ; IFN: interferon ; NK: Natural killer cells; NLR: neutrophil/lymphocyte ratio; PE:
300 pulmonary embolism;sIL-2 α or sCD25: soluble IL-2 receptor alpha; TNF- α : tumor necrosis
301 factor alpha.

302

303 Declarations

- 304
- 305 • The study was approved by the local Ethics Committee (Comité Ético de
306 Investigación Clínica Illes Balears nº IB 4169/20 PI) and was performed in
307 compliance with the Declaration of Helsinki. Informed consent forms were
308 obtained from all participants.
 - 309 • The authors have no conflicts of interest to declare.
 - 310 • This work was supported by a grant from Instituto Salud Carlos III [grant
311 number **COV20/00943**]

311

312

313

314

315

316 References

- 317 1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological
318 Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020[J]. Vol. 2(8).
319 China CDC Weekly, **2020**:113-22.
- 320 2. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected
321 Pneumonia. *N Engl J Med* **2020**; 382:1199-207.
- 322 3. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update.
- 323 4. Cen Y, Chen X, Shen Y, et al. Risk factors for disease progression in patients with mild to moderate
324 coronavirus disease 2019—a multi-centre observational study. *Clin Microbiol Infect* **2020**; 26:1242-7.
- 325 5. Salto-Alejandre S, Roca-Oporto C, Martín-Gutiérrez G, et al. A quick prediction tool for unfavourable
326 outcome in COVID-19 inpatients: Development and internal validation. *J Infect* **2020**.
- 327 6. Ji D, Zhang D, Xu J, et al. Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL
328 Score. *Clin Infect Dis* **2020**; 71:1393-9.
- 329 7. Zheng Y, Xu H, Yang M, et al. Epidemiological characteristics and clinical features of 32 critical and 67
330 noncritical cases of COVID-19 in Chengdu. *J Clin Virol* **2020**; 127:104366.
- 331 8. Chi Y, Ge Y, Wu B, et al. Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus
332 Disease 2019 in China. *J Infect Dis* **2020**; 222:746-54.
- 333 9. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-
334 19) in Wuhan, China. *Clin Infect Dis* **2020**; 71:762-8.
- 335 10. Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and
336 lymphocytes as key clues from a multicentre retrospective study. *Immun Ageing* **2020**; 17:22.
- 337 11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
338 China. *Lancet* **2020**; 395:497-506.
- 339 12. Rodríguez-Baño J, Pachón J, Carratalà J, et al. Treatment with tocilizumab or corticosteroids for COVID-19
340 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). *Clin Microbiol Infect*
341 **2020**.
- 342 13. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung
343 inflammation by COVID-19: anti-inflammatory strategies. *J Biol Regul Homeost Agents* **2020**; 34.
- 344 14. Rao SN, Manissero D, Steele VR, Pareja J. A Systematic Review of the Clinical Utility of Cycle Threshold
345 Values in the Context of COVID-19. *Infect Dis Ther* **2020**; 9:573-86.
- 346 15. Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further
347 clinical severity. *Emerg Microbes Infect* **2020**; 9:469-73.
- 348 16. Chen L, Liu HG, Liu W, et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus
349 pneumonia]. *Zhonghua Jie He He Hu Xi Za Zhi* **2020**; 43:E005.
- 350 17. Berenguer J, Ryan P, Rodríguez-Baño J, et al. Characteristics and predictors of death among 4,035
351 consecutively hospitalized patients with COVID-19 in Spain. *Clin Microbiol Infect* **2020**.
- 352 18. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
353 National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/> .
- 354 19. Dahan S, Segal G, Katz I, et al. Ferritin as a Marker of Severity in COVID-19 Patients: A Fatal Correlation.
355 *Isr Med Assoc J* **2020**; 8:429-34.
- 356 20. Gómez-Pastora J, Weigand M, Kim J, et al. Hyperferritinemia in critically ill COVID-19 patients - Is ferritin
357 the product of inflammation or a pathogenic mediator? *Clin Chim Acta* **2020**; 509:249-51.
- 358 21. Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with
359 hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia,
360 Italy. *Autoimmun Rev* **2020**; 19:102568.
- 361 22. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill
362 adults with COVID-19 in New York City: a prospective cohort study. *Lancet* **2020**; 395:1763-70.
- 363 23. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by
364 SARS-CoV-2: a prospective cohort study. *Eur Respir J* **2020**; 55.

- 365 24. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in
366 Wuhan, China: a retrospective cohort study. *Lancet* **2020**; 395:1054-62.
- 367 25. Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the
368 neutrophil-to-lymphocyte ratio? *BMC Res Notes* **2017**; 10:12.
- 369 26. Riggioni C, Comberiati P, Giovannini M, et al. A compendium answering 150 questions on COVID-19 and
370 SARS-CoV-2. *Allergy* **2020**.
- 371 27. Jiang M, Guo Y, Luo Q, et al. T-Cell Subset Counts in Peripheral Blood Can Be Used as Discriminatory
372 Biomarkers for Diagnosis and Severity Prediction of Coronavirus Disease 2019. *J Infect Dis* **2020**; 222:198-
373 202.
- 374 28. Huang W, Berube J, McNamara M, et al. Lymphocyte Subset Counts in COVID-19 Patients: A Meta-
375 Analysis. *Cytometry A* **2020**; 97:772-6.
- 376 29. Dheir H, Sipahi S, Yaylaci S, Köroğlu M, Erdem AF, Karabay O. Is there relationship between SARS-CoV 2
377 and the complement C3 and C4? *Turk J Med Sci* **2020**.
- 378 30. de Nooijer AH, Grondman I, Janssen NAF, et al. Complement activation in the disease course of COVID-19
379 and its effects on clinical outcomes. *J Infect Dis* **2020**.
- 380 31. Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease
381 severity predictors. *Emerg Microbes Infect* **2020**; 9:1123-30.
- 382 32. Broman N, Rantasärkkä K, Feuth T, et al. IL-6 and other biomarkers as predictors of severity in COVID-19.
383 *Ann Med* **2020**:1-5.
- 384 33. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. *Rev Med*
385 *Viro* **2020**:e2141.
- 386 34. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with
387 Covid-19. *N Engl J Med* **2021**.
- 388 35. Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease
389 severity and RANTES with mild disease. *JCI Insight* **2020**; 5.
- 390 36. Sims JT, Krishnan V, Chang CY, et al. Characterization of the Cytokine Storm Reflects Hyperinflammatory
391 Endothelial Dysfunction in COVID-19. *J Allergy Clin Immunol* **2020**.
- 392 37. Satış H, Özger HS, Aysert Yıldız P, et al. Prognostic value of interleukin-18 and its association with other
393 inflammatory markers and disease severity in COVID-19. *Cytokine* **2020**; 137:155302.
- 394 38. Lin M, Park S, Hayden A, et al. Clinical utility of soluble interleukin-2 receptor in hemophagocytic
395 syndromes: a systematic scoping review. *Ann Hematol* **2017**; 96:1241-51.
- 396 39. Hou H, Zhang B, Huang H, et al. Using IL-2R/lymphocytes for predicting the clinical progression of
397 patients with COVID-19. *Clin Exp Immunol* **2020**; 201:76-84.
- 398 40. Huang JT, Ran RX, Lv ZH, et al. Chronological Changes of Viral Shedding in Adult Inpatients with COVID-19
399 in Wuhan, China. *Clin Infect Dis* **2020**.
- 400 41. Yu X, Sun S, Shi Y, Wang H, Zhao R, Sheng J. SARS-CoV-2 viral load in sputum correlates with risk of
401 COVID-19 progression. *Crit Care*. Vol. 24, **2020**:170.
- 402 42. Liu Y, Liao W, Wan L, Xiang T, Zhang W. Correlation Between Relative Nasopharyngeal Virus RNA Load
403 and Lymphocyte Count Disease Severity in Patients with COVID-19. *Viral Immunol* **2020**.
- 404 43. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis* **2020**;
405 20:656-7.
- 406 44. Feikin DR, Fu W, Park DE, et al. Is Higher Viral Load in the Upper Respiratory Tract Associated With
407 Severe Pneumonia? Findings From the PERCH Study. *Clin Infect Dis* **2017**; 64:S337-s46.
- 408 45. Ng EK, Hui DS, Chan KC, et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA
409 in the plasma and serum of patients with severe acute respiratory syndrome. *Clin Chem* **2003**; 49:1976-80.
- 410 46. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2
411 in Zhejiang province, China, January-March 2020: retrospective cohort study. *Bmj* **2020**; 369:m1443.

412

413

414

415 **Table 1.** Demographic characteristics and comorbidities of SARs-COV-2 infected patients
416 with mild, severe, and critical disease.

	Mild (n = 49)	Severe (n = 32)	Critical (n = 39)
Age, years, median (IQR)	51 (44.5-64.5)	61 (48.5-75-5)	66 (56-73)
Sex, women/men	32/17	16/16	7/32
Days from symptom onset on admission, median (IQR)	10 (4-16)	7 (5-13.7)	7 (5-10)
Chronic cardiovascular disease	9	4	8
Hypertension	13	7	17
COPD	6	3	5
Renal disease (*)	1	2	1
Diabetes	5	3	10
Obesity (body mass index >30)	11	2	10
Pregnancy	2	0	1
Liver cirrhosis	1	1	2
Neurological disease (†)	7	2	5
Active solid/hematological malignancy	4	0	1
HIV infection	3	0	1
Active smoker	12	3	7

417 Abbreviations: COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; SARS-
418 CoV-2, severe acute respiratory syndrome coronavirus 2.

419 (*) included: advanced stage renal disease, transplant recipient or hemodialysis patients.

420 (†) included: cerebral vascular disease and Parkinson disease

421

422 **Table 2.** Comparison of laboratory markers in mild, severe, and critical COVID-19. Median

423 and IQR.

	Mild (n = 47)	Severe (n = 32)	Critical (n = 38)	P value
Ferritin (ng/mL)	117 (69.0-300.0)	437.0 (215.0-709.0)	1107 (582-2435)	<i>P</i> < .001
D-dimer (ng/mL)	218 (106.7-354.2)	291 .0 (187.5-2008.0)	533.0 (290.0- 2153.0)	<i>P</i> = .007
NLR	2,5 (1.9-3.5)	3.6 (2.5-6-8)	8.1 (4.1-13.7)	<i>P</i> < .001
CRP (mg/dL)	0.9 (0.3-4.7)	5,6 (2.8-11.8)	17.4 (10.0- 23.7)	<i>P</i> < .001

424 Abbreviations: COVID-19, coronavirus disease 2019; CRP, C-reactive protein; IQR, interquartile range; NLR,

425 neutrophil/lymphocyte ratio.

426

427

428

429

430

431

432

433

434 **Table 3.** Comparison of cytokine levels on admission in mild, severe, and critical COVID-
435 19.

	Mild n = 41	Severe n = 31	Critical n = 38	P value
IL-6	28.0 (13.0-76.0)	36.0 (18.0-87.0)	218.5 (47.6-819.7)	P < .001
IL-10	0.0 (0.0-14.2)	4.1 (0.0-36.5)	63.1 (21.5-112.9)	P < .001
sIL-2α (sCD25)	519 (364.2-768.0)	701 (474.0-795.0)	972 (579.0-1338.0)	P = .012
IFN	5.1 (1.4-13.0)	11.7 (1.6-39.7)	13.9 (3.1-33.7)	n.s.
IL1β	2.9 (0.9-2.0)	7.9 (1.3-12.3)	11.2 (5.1-18.5)	P = .001
IL-1Ra	47.7 (24.6-96.5)	54.8 (32.0-125.4)	104.5 (49.3-333.0)	P = .001
IL-8	42.8 (14.5-93.9)	51.5 (20.5-116.2)	49.7 (21.7-109.4)	n.s.
IL-17A	0.0 (0.0-2.7)	0.0 (0.0-3.8)	0.0 (0.0-9.17)	n.s.
IL-18	51.0 (17.9-92.4)	46.8 (32.8-93.9)	181.8 (87.3-307.5)	p < .001
IL-22	(0.0-0.0)	0.0 (0.0-72.1)	0.0 (0.0-0.0)	n.s.
TNF	31.8 (19.4-54.9)	37.7 (22.7-63.3)	50.7 (35.7-79.3)	n.s.

436 Abbreviations: COVID-19, coronavirus disease 2019; IFN, interferon; IL-1Ra, IL-1 receptor antagonist; n.s.,
437 not significant; TNF, tumor necrosis factor; sIL-2 α , serum IL-2 receptor alpha.

438

439

440

441

442 **Table 4.** IL-6, IL-10, sIL-2 α (sCD25) ,IL1 β , IL-1Ra, and IL-18 cut-off values and ORs (95%
443 CI) for the risk of developing critical COVID-19 in the age-adjusted univariate and
444 multivariate analyses.

Variable	Cut-off (pg/mL)	OR (95% CI) Univariate model	OR (95% CI) Multivariate model
IL-6	142.5	8.76 (3.56-21.54)	--
IL-10	10.8	20.73 (5.83-73.71)	8.09 (1.73-37.97)
sIL-2α (sCD25)	804.5	12.46 (4.00-38.8)	11.07 (2.39-51.32)
IL1β	4.68	4.57 (1.81-11.53)	--
IL-1Ra	88.4	4,14 (1.82-9.41)	--
IL-18	144.0	16.10 (5.83-44.46)	10.68 (2.87-39.69)

445 Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; IL-1Ra, IL-1 receptor antagonist;
446 OR, odds ratio; sIL-2 α , serum IL-2 receptor alpha (sCD25).

447

448

449

450

451

452

453

454

455

456

457 **Table 5.** Lymphocytes CD3, CD4, CD8, CD4/CD8 ratio, CD19, and NK cells in patients with
458 mild, severe, and critical COVID-19.

	Mild (n = 39)	Severe (n = 23)	Critical (n = 14)	P value
CD3	1411 (986-2137)	938 (639- 1426)	507 (238-938)	<i>P</i> < .05
CD4	950 (653-1390)	794 (463-1034)	256. (163-594)	<i>P</i> = .00
CD8	478 (317-685)	327 (132-408)	190 (63-253)	<i>P</i> = .00
CD19	256 (170-358)	166 (84-218)	93 (74-158)	<i>P</i> < .05
NK	170 (130-287)	143 (72-320)	65 (37-123)	<i>P</i> < .05
CD4/CD8	2.2 (1.5-2.9)	2.1 (1.5-3.4)	2.2 (1.0-2.8)	<i>P</i> > .05

459 Abbreviations: COVID-19, coronavirus disease 2019; NK, natural killer.

460

461

462

463

464

465 **Table 6.** E, N and RdRp median Ct values and IQRs according to symptom severity. IQR.

466

Mild	29.7 (22,2 – 35.3)	31.9 (25.7- 36,2)	25.1 (20.5-32.5)
Severe	27.6 (19.4 – 33.1)	28.0 (21.9-33,9)	27.0 (20.9-34.1)
Critical	26.4 (21.9-29.5)	29.9 (25.5-31.2)	26.9 (22.9-30.4)

467 Abbreviations: Ct, cycle threshold; IQR, interquartile range.

468

469

470

471

472

473

474

475

476

477

478


479

480

481

Figure 1. Performance of ROC curves in predicting critical patients for ferritin, CRP, NLR, IL-10, sCD25 (sIL2 α), and IL-18. The univariate and multivariate logistic regression analysis distinguished critical from mild and severe disease patients

Abbreviations: CRP, C-reactive protein; NLR, neutrophil/lymphocyte ratio; sCD25s (sIL-2 α), serum IL-2 receptor alpha.



482